Start-up Intelligent Implants has been awarded €4.5 million (~USD $5.2 million) blended funding from the European Union EIC Accelerator programme.
Intelligent Implants SmartFuse technology is a wirelessly enabled orthopaedics platform that has been designed to remotely stimulate, control, and monitor bone growth. The goal of the SmartFuse system is to accelerate bone growth and provide remote monitoring of the patient to support real-time clinical decision-making. The first indication for the SmartFuse system will be for use in lumbar spinal fusions.
John Zellmer, CEO and co-founder of Intelligent Implants said, “We are excited to be one of two Swedish companies to receive the prestigious EIC accelerator funding. Being the flagship programme for SMEs, its highly competitive. This funding from the European Commission and our previous Breakthrough Device Designation from the US Food and Drug Administration endorses the large unmet clinical need and the disruptive potential with our approach.I would like to thank the efforts from members of our team, Zaz Ventures, partners and the support from the community here at the AstraZeneca Bioventurehub in Gothenburg.”
Start-up Intelligent Implants has been awarded €4.5 million (~USD $5.2 million) blended funding from the European Union EIC Accelerator programme.
Intelligent Implants SmartFuse technology is a wirelessly enabled orthopaedics platform that has been designed to remotely stimulate, control, and monitor bone growth. The goal of the SmartFuse...
Start-up Intelligent Implants has been awarded €4.5 million (~USD $5.2 million) blended funding from the European Union EIC Accelerator programme.
Intelligent Implants SmartFuse technology is a wirelessly enabled orthopaedics platform that has been designed to remotely stimulate, control, and monitor bone growth. The goal of the SmartFuse system is to accelerate bone growth and provide remote monitoring of the patient to support real-time clinical decision-making. The first indication for the SmartFuse system will be for use in lumbar spinal fusions.
John Zellmer, CEO and co-founder of Intelligent Implants said, “We are excited to be one of two Swedish companies to receive the prestigious EIC accelerator funding. Being the flagship programme for SMEs, its highly competitive. This funding from the European Commission and our previous Breakthrough Device Designation from the US Food and Drug Administration endorses the large unmet clinical need and the disruptive potential with our approach.I would like to thank the efforts from members of our team, Zaz Ventures, partners and the support from the community here at the AstraZeneca Bioventurehub in Gothenburg.”
Copy to clipboard 
